Related Experiment Videos

Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells

Sepideh Shaker1, Mark Bernstein, Richard L Momparler

  • 1Département de Pharmacologie, Université de Montréal, Montréal, Québec H3T 1C5, Canada.

Oncology Reports
|May 13, 2004
PubMed

Insights

Combining DNA methylation inhibitor 5-aza-2'-deoxycytidine (5AZA) with histone deacetylase inhibitor depsipeptide (depsi) effectively suppressed lymphoma cell growth and reactivated the E-cadherin gene.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Epigenetic modifications, including DNA methylation and histone deacetylation, are implicated in silencing tumor suppressor genes during leukemogenesis.
  • Aberrant epigenetic changes are a hallmark of various cancers, including lymphoma.

Purpose of the Study:

  • To evaluate the in vitro antineoplastic and gene re-activation effects of 5-aza-2'-deoxycytidine (5AZA) and depsipeptide (depsi) on Raji lymphoma cells.
  • To investigate the synergistic potential of combining 5AZA and depsi in inhibiting lymphoma cell growth and reactivating silenced genes.

Main Methods:

  • Treatment of Raji lymphoma cells with 5AZA (DNA methylation inhibitor) and/or depsipeptide (histone deacetylase inhibitor).
  • Assessment of cell growth inhibition and colony formation.
  • Reverse transcription-polymerase chain reaction (RT-PCR) to analyze gene expression, specifically E-cadherin.

Main Results:

  • The combination of 5AZA and depsi demonstrated significantly greater inhibition of Raji cell growth and colony formation compared to either agent alone.
  • Co-treatment with 5AZA and depsi synergistically activated the expression of E-cadherin, a gene known to be silenced by aberrant DNA methylation in Raji cells.
  • Evidence suggests cross-talk between DNA methylation and histone modifications in regulating E-cadherin expression in this cell line.

Conclusions:

  • The combination of 5AZA and depsi exhibits potent in vitro antineoplastic activity against Raji lymphoma cells.
  • This drug combination effectively reactivates the epigenetically silenced E-cadherin gene, indicating a potential therapeutic strategy.
  • The findings suggest that 5AZA and depsi represent a promising combination for further investigation in lymphoma patients.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.